Exton’s Fibrocell Science has made some changes in its leadership by appointing John Maslowski as Chief Executive Officer and Douglas Swirsky as Chairman of the Board of Directors.

Maslowski, who succeeds David Pernock effective immediately, has also been appointed to the board.

“During 2016, Fibrocell has completely transitioned to a clinical-stage, gene therapy company, and we are confident that, under John’s leadership, its significant momentum will continue,” said Swirsky. “We look forward to fulfilling the promise of our proprietary fibroblast platform for patients suffering from rare, devastating genetic diseases of the skin and connective tissue.”

Maslowski joined the gene therapy company over a decade ago, and recently served as Fibrocell’s Senior Vice President of Scientific Affairs. Prior to that, he was Vice President of Operations, in charge of manufacturing and quality operations.

Before joining the company, Maslowski worked for several prominent companies in the pharmaceutical field, including Wyeth, Merck, and Teva. His qualifications include a B.S. in Biology from Ursinus College, as well as an M.S. in Biology from Villanova University.

“I am honored to be appointed CEO of Fibrocell and have the opportunity to lead our dedicated team as we move into 2017 and beyond,” said Maslowski.

Check out previous VISTA Today coverage of Fibrocell here.